American Healthcare REIT, Inc.

Valuation Analysis

About the Company

American Healthcare REIT, Inc. en bref

American Healthcare REIT, Inc. (AHR) is currently trading at 40,55 € with a market capitalization of 7,8 Md €. The trailing P/E ratio stands at 78.83x, with a forward P/E of 54.08x. The 52-week range spans from 30,91 € to 47,66 €; the current price is 14.9% below the yearly high. Year-over-year revenue growth stands at +20.9%. The net profit margin stands at 4.23%.

💰 Dividende

American Healthcare REIT, Inc. pays an annual dividend of 0,87 € per share, representing a yield of 2.15%. The payout ratio stands at 169.49%. The elevated payout ratio reflects a mature dividend policy.

📊 Avis des analystes

13 analystes évaluent American Healthcare REIT, Inc. (AHR) au consensus : Acheter. L'objectif de cours moyen est de 51,30 €, soit un potentiel de +26.52% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 47,95 € à 58,41 €.

American Healthcare REIT, Inc. : la thèse d'investissement en détail

American Healthcare REIT, Inc. (AHR) operates in the Real Estate — specifically REIT - Healthcare Facilities — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 20.9% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Wall Street consensus sits at Buy with an average price target implying roughly 26.52% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

With a net margin of just 4.23%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valorisation en contexte

The EV/EBITDA multiple of 25.58x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

À surveiller

• The forward P/E of 54.08x is meaningfully below the trailing 78.83x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 26.52% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (8.24%).

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy American Healthcare REIT, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.